Lantern Pharma (NASDAQ:LTRN) Stock Rating Lowered by Wall Street Zen

Posted by on Aug 17th, 2026

Lantern Pharma (NASDAQ:LTRN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings raised Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Lantern Pharma has a consensus rating of “Sell”.

View Our Latest Analysis on Lantern Pharma

Lantern Pharma Price Performance

LTRN opened at $2.65 on Friday. Lantern Pharma has a 1-year low of $1.11 and a 1-year high of $4.75. The stock’s 50 day simple moving average is $3.31 and its 200 day simple moving average is $2.85. The stock has a market cap of $33.81 million, a P/E ratio of -1.64 and a beta of 2.35.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.19).

Institutional Investors Weigh In On Lantern Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Empery Asset Management LP acquired a new stake in Lantern Pharma in the second quarter worth $3,513,930,000. Susquehanna International Group LLP bought a new stake in Lantern Pharma in the 3rd quarter worth about $170,000. BlackRock Inc. purchased a new position in shares of Lantern Pharma in the 2nd quarter worth about $93,000. Bank of New York Mellon Corp bought a new stake in shares of Lantern Pharma in the 2nd quarter worth approximately $89,000. Finally, Vanguard Group Inc. lifted its position in shares of Lantern Pharma by 5.6% during the 3rd quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock valued at $1,671,000 after buying an additional 20,321 shares during the last quarter. 28.62% of the stock is owned by institutional investors.

About Lantern Pharma

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.

Read More

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.